home / stock / sabsw / sabsw quote
Last: | $0.05 |
---|---|
Change Percent: | -30.55% |
Open: | $0.05 |
Close: | $0.05 |
High: | $0.05 |
Low: | $0.040049 |
Volume: | 3,970 |
Last Trade Date Time: | 07/18/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$0.05 | $0.05 | $0.05 | $0.05 | $0.040049 | 3,970 | 07-18-2024 |
$0.0383 | $0 | $0.0383 | $0 | $0 | 30 | 07-17-2024 |
$0.0383 | $0.0383 | $0.0383 | $0.0383 | $0.0383 | 620 | 07-12-2024 |
$0.0403 | $0.04 | $0.0403 | $0.05 | $0.0347 | 3,595 | 07-11-2024 |
$0.0448 | $0.04 | $0.0448 | $0.0642 | $0.0275 | 22,771 | 07-10-2024 |
$0.0379 | $0.0598 | $0.0379 | $0.0598 | $0.0352 | 2,434 | 07-09-2024 |
$0.0599 | $0.06 | $0.0599 | $0.06 | $0.0591 | 3,069 | 07-08-2024 |
$0.0596 | $0.048 | $0.0596 | $0.0597 | $0.048 | 11,066 | 07-05-2024 |
$0.0493 | $0.0493 | $0.0493 | $0.0493 | $0.0493 | 1,787 | 07-04-2024 |
$0.0493 | $0.0493 | $0.0493 | $0.0493 | $0.0493 | 1,787 | 07-03-2024 |
$0.05 | $0.0599 | $0.05 | $0.0599 | $0.05 | 15,596 | 07-02-2024 |
$0.0541 | $0.0351 | $0.0541 | $0.0598 | $0.033 | 8,980 | 07-01-2024 |
$0.0474 | $0.0474 | $0.0474 | $0.0474 | $0.0474 | 4,115 | 06-28-2024 |
$0.035 | $0.035 | $0.035 | $0.035 | $0.035 | 1,004 | 06-27-2024 |
$0.037601 | $0.0399 | $0.037601 | $0.0456 | $0.0351 | 50,828 | 06-26-2024 |
$0.0398 | $0.0398 | $0.0398 | $0.0398 | $0.0398 | 16,192 | 06-25-2024 |
$0.0398 | $0.0397 | $0.0398 | $0.0398 | $0.0397 | 935 | 06-24-2024 |
$0.05 | $0.05 | $0.05 | $0.05 | $0.05 | 10,759 | 06-21-2024 |
$0.06 | $0.05 | $0.06 | $0.0623 | $0.05 | 24,754 | 06-20-2024 |
$0.0397 | $0.04 | $0.0397 | $0.04 | $0.0397 | 619 | 06-19-2024 |
News, Short Squeeze, Breakout and More Instantly...
SAB Biotherapeutics Inc. Warrant Company Name:
SABSW Stock Symbol:
NASDAQ Market:
SAB Biotherapeutics Inc. Warrant Website:
New name, logo and website updates, stock symbol will remain SABS With new brand identity, SAB BIO continues drive towards serious unmet needs in type 1 diabetes MIAMI, June 20, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS) (the “Company” or “SAB...
MIAMI, June 18, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS) (the “Company” or “SAB”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform developing a human anti-thymocyte immunoglobulin (hIgG) for delaying the onset or progre...
MIAMI, May 30, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS) (the “Company” or “SAB”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform developing a human anti-thymocyte immunoglobulin (hIgG) for delaying the onset or progres...